We have identified a novel gene, six transmembrane protein of prostate 2 (STAMP2), named for its high sequence similarity to the recently identified STAMP1 gene. STAMP2 displays a tissue-restricted expression with highest expression levels in placenta, lung, heart, and prostate and is predicted to code for a 459-amino acid six transmembrane protein. Using a form of STAMP2 labeled with green flourescent protein (GFP) in quantitative time-lapse and immunofluorescence confocal microscopy, we show that STAMP2 is primarily localized to the Golgi complex, trans-Golgi network, and the plasma membrane. STAMP2 also localizes to vesicular-tubular structures in the cytosol and colocalizes with the Early Endosome Antigen1 (EEA1) suggesting that it may be involved in the secretory/endocytic pathways. STAMP2 expression is exquisitely androgen regulated in the androgen-sensitive, androgen receptor-positive prostate cancer cell line LNCaP, but not in androgen receptornegative prostate cancer cell lines PC-3 and DU145. Analysis of STAMP2 expression in matched normal and tumor samples microdissected from prostate cancer specimens indicates that STAMP2 is overexpressed in prostate cancer cells compared with normal prostate epithelial cells. Furthermore, ectopic expression of STAMP2 in prostate cancer cells significantly increases cell growth and colony formation suggesting that STAMP2 may have a role in cell proliferation. Taken together, these data suggest that STAMP2 may contribute to the normal biology of the prostate cell, as well as prostate cancer progression.
Introduction
Androgens have a critical role in the development and maintenance of the male reproductive system and have roles in physiological and pathological conditions, including the normal prostate and prostate cancer (for reviews, see Jenster, 1999; Kokontis and Liao, 1999; Roy et al., 1999) . In the initial stages, prostate cancer is dependent on androgens for growth which is the basis for androgen ablation therapy (Huggins et al., 1941) . However, in most cases, prostate cancer progresses to an androgen-independent phenotype for which there is no effective therapy available at present (for reviews, see Coffey, 1993; Crawford et al., 1999) .
Despite the recognition of the role of androgens in prostate biology and pathophysiology for more than 60 years, the molecular mechanisms that are responsible for the effects of androgens are largely unknown. Recent studies have begun to identify androgen-regulated and prostate-enriched genes and the proteins that they encode which started to define the molecular details of androgen action in the prostate and in prostate carcinogenesis. The best known of these genes is Kallikrein 3 (KLK3), also called prostate-specific antigen (PSA), that is a widely used clinical tumor marker for detection and monitoring of prostate cancer progression (Stephan et al., 2002) . Other androgenregulated genes that are primarily expressed in the prostate include KLK2 (Rittenhouse et al., 1998) , KLK4 (Nelson et al., 1999; Stephenson et al., 1999; Yousef et al., 1999; Korkmaz et al., 2001) , NKX3.1 (Bieberich et al., 1996; He et al., 1997) , and PCGEM (Srikantan et al., 2000) . Recent high-throughput screening by various approaches has identified a number of genes which are up-or downregulated in response to androgens that await further characterization (e.g. Korkmaz et al., 2000; Xu et al., 2001; Nelson et al., 2002) .
While searching for genes that are differentially expressed during early stages of prostate cancer (Korkmaz et al., 2000) , we have cloned a novel gene, six transmembrane protein of prostate 2 (STAMP2), named for its high sequence similarity to STAMP1, a highly prostate-enriched gene that is overexpressed in prostate cancer (Korkmaz et al., 2002) . We show that STAMP2 is a highly androgen-regulated gene in androgen receptor-positive prostate cancer cells, but not in androgen receptor-negative cells. Live-cell imaging of green fluorescent protein (GFP)-tagged STAMP2 and indirect immunofluorescence microscopy of STAMP2 distribution indicated that STAMP2 is localized to the Golgi, trans-Golgi network (TGN), and the plasma membrane and may have a role in endocytic/ secretory trafficking pathways. Furthermore, STAMP2 expression is increased in prostate cancer compared with matched normal prostate epithelial cells microdissected from the same radical prostatectomy specimens. In addition, ectopic expression of STAMP2 in a prostate cancer cell line increases cell proliferation. These data suggest that STAMP2 may have a key role in normal prostate physiology, as well as progression of prostate cancer.
Results

Isolation and characterization of the STAMP2 gene and mRNA
While searching for genes that are similar to STAMP1 (Korkmaz et al., 2002) , we identified a BAC clone (GenBank Accession # AC003991) on human Chr7q21 that showed significant sequence similarity to STAMP1 cDNA ( Figure 1a ). Computational exon/intron junction analysis of this locus and alignment of the full-length cDNA sequence revealed that there is a gene at this locus that is composed of five exons and four introns which is similar to STAMP1 cDNA along its whole sequence (Figure 1a ). Given the similarity in both the gene structure, the predicted amino-acid sequence (44% identity, 64% conservation), as well as the similarities in intracellular distribution to STAMP1 (see below), we named this gene STAMP2. The STAMP2 gene spans around 26 kb which is in part due to the extremely large size of intron 1 (22 516 bp).
STAMP1 and STAMP2 both lie on Chr7q, but are transcribed in opposite directions (Figure 1b) . The STAMP1 related gene, six transmembrane epithelial antigen of prostate (STEAP) (Hubert et al., 1999) , is also in this locus and is transcribed in the same direction as STAMP1. Thus, Chr7q contains a cluster of genes predicted to encode six transmembrane proteins.
We cloned the full-length cDNA for STAMP2 from an R1881-induced LNCaP cDNA library using PCR. The predicted amino-acid sequence is presented in Figure 2 . Since in Northern analysis STAMP2 mRNA runs as a 4.0 kb band (see below) and the cDNA we cloned is 2.3 kb including the poly (A) tail, STAMP2 mRNA is predicted to have approximately 1.7 kb of 5 0 -UTR (data not shown).
BLAST search of GenBank with the STAMP2 cDNA revealed that it may be homologous (78% identity on the predicted amino-acid level) to the previously described tumor necrosis factor a-induced adiposerelated protein (TIARP) (Moldes et al., 2001) , a mouse protein that may have a role in adipocyte differentiation ( Figure 3 ). In addition to TIARP and STAMP1, STAMP2 displays significant similarity to the rat protein pHyde (Steiner et al., 2000) (Figure 3 ). When pHyde is overexpressed, it causes apoptosis in prostate cancer cells, and human homolog of pHyde, TSAP6, regulates apoptosis and cell cycle through interactions with Nix and Myt1 kinase (Passer et al., 2003) . These data suggest that STAMP1, STAMP2, and pHyde/ TSAP6 are structurally, and possibly also functionally, related proteins.
In addition to the six transmembrane domains in the C-terminal half of the predicted STAMP2 sequence (Figure 2 ), a conserved domain search identified three motifs in the N-terminal domain of STAMP2. The first is a predicted dinucleotide-binding domain that is found in a number of bacterial proteins (Deppenmeier, 2002) . Second is an NADP oxidoreductase motif that is coenzyme F420-dependent, such as F420H2 : NADP þ oxidoreductase found in archeabacteria (Warkentin et al., 2001) . Third is a motif that resembles pyrroline 5-carboxylate reductase, an enzyme that is involved in amino-acid transport and metabolism (Phang, 1985 
STAMP2 has a restricted tissue distribution
We next determined the expression profile of STAMP2 in various human tissues by Northern analysis in which a multiple tissue Northern blot was hybridized to the STAMP2 cDNA probe. As shown in Figure 4a , STAMP2 hybridized to a major mRNA species of 4.0 kb in placenta, lung, heart, and prostate, with substantially lower expression also seen in liver, skeletal muscle, pancreas, testis, and small intestine; there was no detectable expression in brain, kidney, spleen, colon or peripheral blood leukocytes. Hybridization with a glyceraldehyde 3-phosphate dehydrogenase (G3PDH) cDNA probe resulted in approximately similar signals in all lanes, except for the heart and skeletal muscle where G3PDH mRNA is known to be more abundant compared with other tissues.
Characterization of STAMP2 expression in cell lines and its androgen regulation
Since one of the tissues in which STAMP2 is highly expressed is the prostate, where androgen is a major hormonal stimulus for growth and for early stage prostate cancer (Huggins, 1941) , we assessed the possible androgen regulation of STAMP2 by Northern analysis in the androgen responsive prostate cancer cell line LNCaP (Horoszewicz et al., 1983) . Cells were either left untreated or treated with the synthetic androgen R1881 for 24 h, harvested, total RNA was isolated and used in Northern analysis with STAMP2 cDNA as probe. As shown in Figure naturally occurring androgens testosterone and dihydrotestosterone (data not shown). In contrast, there was no significant difference in the mRNA accumulation of STAMP1 in the same samples, consistent with previous findings (Korkmaz et al., 2002) . Similar to STAMP1, there was no detectable expression of STAMP2 in a number of prostate cancer cell lines that do not express the androgen receptor (PC-3, DU-145, CA-HPV10, PZ-HPV7, YPEN-1).Whereas STAMP2 expression was dose dependent for R1881, there was no STAMP2 expression in PC-3 or DU-145 cells even at higher concentrations of hormone (data now shown). In addition, STAMP2 was not expressed in myotubes (C2), lung cancer cells (NCI-H661), breast cancer cells (MCF7, MCF7-LCC1, MCF7-LCC2, MB435), or cervical carcinoma cells (HeLa) (Figure 4b ). Time course analysis of androgen treatment revealed that STAMP2 expression begins around 6 h and increases through 48 h (Figure 4c ). These data support the finding that STAMP2 is expressed in a tissue-restricted manner and that it is an androgen target gene in LNCaP cells.
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Intracellular localization of STAMP2
To gain insight into the cellular localization pattern of STAMP2, we labeled it with the GFP to generate GFP-STAMP2. Such use of GFP fusion proteins is frequently used to assess intracellular localization and dynamics of proteins (for a review, see Tsien, 1998) . COS-1 cells were transiently transfected with pEGFP-C1-STAMP2, fixed and processed for confocal microscopy. A representative single optical section of a COS-1 cell is shown in Figure 5a . GFP-STAMP2 displays a strong juxtanuclear distribution that is typical of the Golgi complex. Additionally, significant GFP-STAMP2 distribution was observed in the cell periphery and in vesicular or tubular-shaped bright spots throughout the cytoplasm suggesting that STAMP2 localizes to plasma membrane (PM) and to vesiculotubular structures (VTS) in the cytosol (Figure 5a ). At higher exposures, GFP-STAMP2 distribution can also be seen as a light reticular pattern in the cytosol, reminiscent of the endoplasmic reticulum ( Figure 5a , right panel). We have directly assessed whether GFP-STAMP2 is associated with the Golgi complex. We compared the intracellular distribution of GFP-STAMP2 with those of three-well characterized Golgi markers, the coat protein b-COP (Pepperkok et al., 1993) , mid-Golgi marker giantin (Linstedt and Hauri, 1993) , and TGN marker TGN-46 (Ponnambalam and Banting, 1996) . GFP-STAMP2 was transfected into COS-1 cells, which were then fixed, labeled with the appropriate primary and secondary antibodies, and then single optical sections were acquired by laser scanning confocal Characterization of STAMP2 expression. (a) A multiple tissue Northern blot (Clontech) was probed with STAMP2 or G3PDH cDNA. The stronger hybridization that is observed with G3PDH in the heart and skeletal muscle samples is due to its higher expression in these tissues. The lanes represent: 1.heart, 2. brain, 3. placenta, 4. lung, 5. liver, 6. skeletal muscle, 7. kidney, 8. pancreas, 9. spleen, 10. thymus, 11. prostate, 12. testis, 13. ovary, 14. Figure 5b , there was significant overlap of GFP-STAMP2 juxtanuclear distribution with Golgi and TGN markers, but there were also some differences. This suggests that STAMP2, at least in part, is differentially localized within the Golgi complex compared with these three markers. There was rapid trafficking of GFP-STAMP2 in the cytosol in the form of predominantly VTS (Figure 6 ). Some of the VTS followed straight or curvilinear paths, some moved in a stop-and-go fashion, and some showed saltatory movements (see the Quicktime movie). The movement of one such VTS from cytoplasm to cell periphery is shown in consecutive images in Figure 6 . These data suggest that STAMP2 is associated with the secretory pathway.
To probe whether GFP-STAMP2 was associated with the endocytic pathway, we compared the intracellular distribution of GFP-STAMP2 with that of the early endosome protein EEA1 (Stenmark et al., 1996) . GFP-STAMP2 was transfected into COS-1 cells, which were then fixed, immunostained with EEA1 antibodies, and observed by laser scanning confocal microscopy. As shown in Figure 7 , EEA1 had similar intracellular distribution in both transfected and untransfected cells. GFP-STAMP2 significantly colocalized with EEA1 both in the cell periphery and also in the perinuclear area (Figure 7) suggesting that STAMP2 is associated with early endosomes and the endocytic pathway.
Analysis of STAMP2 expression in normal vs adenocarcinoma of prostate
Since prostate is one of the tissues in which STAMP2 is highly expressed, as well as the exquisite androgen regulation of STAMP2 in androgen receptor-positive prostate cancer cells, we studied its expression in normal prostate epithelial cells compared with adenocarcinoma of prostate. To that end, laser capture microdissection (LCM) (Bonner et al., 1997) was used on human radical prostatectomy specimens that were snap frozen immediately upon resection. Normal epithelial cells and cancer cells from the same specimen were collected (matched normal/tumor pair). Total RNA was extracted, cDNA was made, and was then used in quantitative RT-PCR with STAMP2-specific primers. STAMP2 expression in normal/tumor pairs from 26 independent patient samples was compared by statistical analysis as presented in Figure 8 . STAMP2 expression was significantly higher in tumors compared with normal glands (P ¼ 0.002). These data indicate that STAMP2 may have a role in the genesis of, and be a marker for, prostate cancers.
Ectopic expression of STAMP2 increases colony formation and cell proliferation
To determine if STAMP2 may have a role on cell proliferation, we performed colony formation assays. We chose the prostate cancer cell line PC3 which does not express STAMP2. PC3 cells were transfected either with an empty expression vector or an expression vector specifying STAMP2. Cells were then cultured in the presence of G418 for which a resistance gene is present in the plasmids used in transfection. After 2 weeks, cells were fixed and stained to visualize the colonies formed. As shown in Figure 9a and b, there were significantly higher number of colonies in the STAMP2-transfected cells that also gave rise to larger colonies.
This result suggested that STAMP2 may have a role in cell proliferation. To assess this possibility, COS7 cells were transfected with a plasmid specifying expression of GFP together with an empty expression plasmid, or GFP plasmid together with a STAMP2 expression plasmid. Cells were fixed at the indicated times and the GFP-positive cells were counted using a FACS machine. As shown in Figure 9c , STAMP2-containing cells grew significantly faster compared with cells that contained only GFP. Similar results were obtained using DU145 cells (Figure 9d ). These data indicate that STAMP2 has a role in cell proliferation.
Discussion
STAMP2 is the first androgen-regulated six transmembrane protein identified to date. Identification of androgen target genes has been a major focus in recent years given the importance of androgens both in normal physiology and pathological conditions. Since a number of six transmembrane proteins were previously implicated in disease states, such as the multidrug resistance proteins interfering with treatment of various cancers (Haass, 1996) and ATP-binding cassette (ABC) transporters in Tangier's disease (Ordovas, 2000) , it is tempting to speculate that STAMP2 may be involved in similar functions with implications for both the STAMP2 was identified due to its strong sequence similarity to STAMP1 (Korkmaz et al., 2002) . In addition to being on the same region on Chr7q with STAMP1 and STEAP (Hubert et al., 1999) Figure 6 Time-lapse microscopy of GFP-STAMP2 trafficking in living cells. A COS-1 cell transiently expressing GFP-STAMP2 was observed by live-cell confocal microscopy at 371C. Eight consecutive images were taken at 3 s intervals. The movement of a particular vesicular structure from cytoplasm to plasma membrane is shown (white arrows) within the region of the cell that is magnified (white square). Note that the results shown are representative of multiple time-lapse analyses and the changes in the images are not due to movement from the plain of focus
Database searches identified the mouse protein TIARP (Moldes et al., 2001) as the most similar (78% identity) protein to STAMP2 raising the possibility that they are homologous. TIARP was identified as a tumor necrosis factor (TNF) a response gene that is dramatically induced during adipocyte differentiation in mouse cells. In response to TNF a stimulation, TIARP localizes to the plasma membrane suggesting that it may act as a channel or receptor on the mature adipocyte (Moldes et al., 2001) . Whether STAMP2 has a similar function and whether it is involved in adipogenesis in humans requires further work.
To our knowledge, STAMP2 is the first androgenregulated six transmembrane protein described to date that is localized to the Golgi, TGN, plasma membrane, and early endosomes. Most Golgi resident proteins contain type II transmembrane domains (Kleene and Berger, 1993; Natsuka et al., 1994) . Expression of STAMP1 and STAMP2 in the Golgi suggests that six transmembrane proteins may have unique functions in this organelle compared with the other Golgi resident proteins identified so far. Photobleaching experiments provided evidence that GFP-STAMP2 is rapidly exchanged between different parts of the Golgi with kinetics consistent for it being a transmembrane protein (data not shown), supporting the notion that it indeed functions as a transmembrane protein in the Golgi. Further work is needed for the biochemical and functional characterization of STAMP2 in the Golgi.
Consistent with the central role of the Golgi complex in the secretory pathway (Lippincott-Schwartz et al., 1998; Donaldson and Lippincott-Schwartz, 2000; Lemmon and Traub, 2000; Mellman, 2000) , STAMP2 is found in VST structures in the cytosol and colocalizes with EEA1, an early endosome marker (Stenmark et al., 1996) . The significant STAMP2 distribution in the plasma membrane, and the movement of STAMP2 within transport vesicles to and from the plasma membrane in live-cell imaging studies suggest that STAMP2 may be involved in the secretory and endocytic pathways. It is interesting to note that although prostate is a major secretory organ (Cunha et al., 1987) , there is very limited specific information about the functioning of the Golgi in the prostate. Functional characterization of STAMP2 in the future, along with that of STAMP1, should be very useful in this regard. In addition to the localization of GFP-STAMP2 in the Golgi, TGN, and the plasma membrane, a fraction of the GFP-STAMP2 protein can also be detected in the endoplasmic reticulum (ER). ER is the central organelle that is necessary for proper folding and delivery of proteins. Proteins destined for secretion, the plasma membrane or the cell surface, are translocated from the cytoplasm into the ER for further delivery of these proteins to their site of action. Since proteins are translocated into the ER in an unfolded state, it is the primary function of this organelle to modify and fold the translocated proteins to acquire their biologically active conformation (Haigh and Johnson, 2002) . We do not know the significance of the presence of STAMP2 in the ER, or whether it has a functional role in this organelle. However, since the majority of STAMP2 expression is in the Golgi, TGN, early endosomes and the plasma membrane, it is tempting to speculate that GFP-STAMP2 that is in ER is unfolded and is kept in the ER for further processing. Alternatively, there may be a functional role of STAMP2 in the ER. Further work will shed light on this area. STAMP2 is not expressed in a number of ARnegative prostate cancer cell lines (PC-3, DU-145, CA-HPV10, PZ-HPV7, YPEN-1), but is expressed at high levels in the AR-positive cell line LNCaP. Thus, expression of STAMP2 is correlated with the presence of a functional AR in the cell consistent with its androgen regulation. Whether AR directly binds to regulatory sites of the STAMP2 gene will require the characterization of STAMP2 flanking sequences and further functional studies.
In the prostate cancer samples, there was no correlation between the levels of AR and STAMP2 expression (data not shown). This suggests that AR transactivation potential may not correlate with AR expression in these samples or that there are other factors which are involved in regulating STAMP2 expression in the prostate. Further work is required to assess these possibilities.
It has been known for over 60 years that androgens play a key role both in the development and maintenance of the normal prostate and the initiation and progression of prostate cancer (Huggins et al., 1941) . This is the basis for androgen withdrawal therapy that unfortunately fails in most cases after a few months or years. Despite this knowledge, the molecular mechanisms of androgen action in the prostate remain poorly described at present. Given the exquisite androgen regulation of STAMP2, its significant expression in the prostate, and overexpression in a subset of prostate cancers, it may prove to be a useful tool in diagnostic and therapeutic applications, in addition to helping define the molecular dynamics of the prostate cancer cell.
Materials and methods
Cell culture
All prostate cancer cell lines were routinely maintained and treated as previously described (Korkmaz et al., 2000) . Briefly, the cells were routinely maintained in RPMI 1640 medium (Gibco-BRL), supplemented with 10% fetal calf serum (FCS), penicillin/streptomycin (5 mg/ml), and L-glutamine (200 mM). For androgen induction and RNA preparation, cells were grown for 48 h in RPMI 1640 containing 2% FCS that was charcoal-treated (CT) to remove steroids, followed by an additional 24 h in RPMI 1640 containing 0.5% CT-FCS. The synthetic androgen R1881 (10 À8 M) (Dupont-NEN) was then added and cells were collected at the indicated time points. Total RNA was then prepared by the single-step guanidine thiocyanate procedure and used in Northern analysis. All other cell lines were cultured in DMEM supplemented with 10% FCS, penicillin/streptomycin (5 mg/ml), and L-glutamine (200 mM).
Colony formation assay
PC3 cells were either transfected with an empty expression plasmid pCDNA3 or one that encodes full-length STAMP2 cDNA. At 24 h after transfection, cells were trypsinized and seeded on new plates (10 000 cells/100 mm dish). Selection antibiotic (G418, Sigma) was added and cells were cultured for 2 weeks. Cells were then fixed with cold methanol at À201C for 30 min. The colonies formed were stained with crystal violet (0.1%) and the area covered on each plate by the colonies were measured using an imaging system (Syngene).
Cell proliferation assay
For the cell proliferation assay by flow cytometry, 4 Â 10 5 cells were plated per 10-cm dish the day before transfection. Cells were transfected with 5 mg of DNA (4 mg of pcDNA3 or pcDNA3-STAMP2 together with 1 mg of pEGFP-C1) using FuGene 6 (Roche). At 24 h after transfection, one part of transfected cells were analysed by flow cytometry and the other part was cultured in 10-cm dishes and harvested at the indicated times for flow cytometry. For analysis of flow cytometry results, a Becton Dickinson FACSCalibur flow cytometer with Cell Quest software was used to determine the number of GFP-positive cells among transfected cells. A total of 200 000 single cells were analysed per sample. The data presented are the means7s.d. of three independent experiments shown as the ratio of the number of GFP-positive cells that were cotransfected either with pcDNA3-STAMP2 or the empty vector pcDNA3.
Cloning and plasmid construction
While working on characterization of STAMP1 (Korkmaz et al., 2002) , we searched GenBank for sequences that are similar to STAMP1. Several partial cDNA clones as well as genomic clones were identified for a novel gene that we termed STAMP2. These STAMP2 clones were then used to computationally construct a full-length cDNA. Primers were designed on the basis of this sequence and used in PCR to amplify the full-length STAMP2 cDNA from an LNCaP SMART (Clontech) cDNA library. The amplified cDNA product was cloned into pCRII-TOPO, or pcDNA4-HisMax (Invitrogen, CA, USA) and sequenced on both strands. In addition, the resulting cDNA sequence was aligned with the gene sequence (BAC AC003991) to determine gene structure and sequence accuracy.
The full-length STAMP2 ORF from pCRII-TOPO-STAMP2 was fused in frame to the C-terminus of GFP using the vector pEGFP-C1 (Clontech) to generate GFP-STAMP2.
DNA sequence analysis
For DNA sequencing, BigDye kit (Perkin Elmer), and automated dye termination system services of GATC, Germany, was used. The DNA sequences were analysed by standard algorithms accessible at various web sites, including NCBI-BLAST, Clustal 1.8, and Gendoc 2.6.
Protein sequence analysis
Primary sequence analysis for STAMP1 was performed by BLAST at http://www.ncbi.nlm.nih.gov/BLAST/. Secondary protein structure predictions were performed by using the web tools SMART, at http://smart.embl-heidelberg.de/, SOSUI at http://sosui.proteome.bio.tuat.ac.jp/sosuiframe0E.html, and PSORT at http://psort.nibb.ac.jp/.
Northern analysis
Total RNA was prepared by the single-step guanidine thiocyanate procedure and used in Northern analysis (Ausebel et al., 1997) . Total RNA (15 mg) was used per lane. Probes were generated by random priming and had a specific activity of >3 Â 10 8 d.p.m/mg. A full-length cDNA (1-2263 bp) of STAMP2 (GenBank Accession number # AF423422) was used as probe. Bands were visualized and quantitated by phosphorimager analysis (Molecular Dynamics).
Confocal microscopy and live-cell imaging COS-1 cells were transfected by Fugene (Roche). Cells were grown either on cover slips placed in six-well tissue culture plates for indirect immunofluorescence microscopy or on LabTek Chambered Coverglass (Nalge Nunc International) for live-cell microscopy. For immunoflourescence, transiently transfected cells were observed for GFP-STAMP2 expression 18 h after transfection using a Leica TCS-SP laser scanning confocal microscope with the 488 nm Argon laser line. All livecell experiments were carried out on a Zeiss 510 laser scanning confocal microscope using a 100 Â /1.3 N.A. oil immersion objective and 488 nm argon laser line at 371C. Imaging was carried out in the Fluorescence Imaging Facility, Laboratory of Receptor Biology and Gene Expression, National Cancer Institute.
Indirect immunofluorescence
Indirect immunofluorescence was carried out as previously described (Misteli and Spector, 1999) . The following antibodies were used: anti-b-coat protein (b-COP) (Affinity Bioreagents), anti-giantin (Covance), anti-TGN46 (Serotec), and anti-EEA1 (BD Transduction Labs). Texas Red-conjugated secondary antibodies specific for mouse and rabbit were purchased from Jackson Immunoresearch Laboratories.
Prostate tissue preparation and microdissection
Radical prostatectomy specimens were obtained at Aker University Hospital and snap frozen upon resection. Sections were obtained and microdissected by a pathologist using LCM as previously described (Bonner et al., 1997) .
Quantitative RT-PCR
Total RNA was extracted from the LCM samples using Absolutely RNAt Microprep Kit (Stratagene), including DNAse treatment. RNA was used for first-strand cDNA synthesis with the Superscript II system (Invitrogen). STAMP2 expression level was determined using the Light Cycler Instrument (Roche, Mannheim, Germany), with the Light Cycler-FastStart DNA Master SYBR Green I Kit (Roche). The primers used were Forward: 5 0 -ATG ACA GCA AAG CCA AGC AA-3 0 , and Reverse: 5 0 -GCA AAG CAT CCA GTG GTC AA-3 0 . A standard curve made from serial dilutions of cDNA was used to calculate the relative amount of STAMP2 in each sample. These values were then normalized to the relative amount of the internal standard ATP6 Synthase (ATP-6) in the same samples, calculated from a standard curve established in the same way. Primers used for ATP-6 amplification were Forward: 5 0 -CAG TGA TTA TAG GCT TTC GCT CTA A-3 0 , and Reverse: 5 0 -CAG GGC TAT TGG TTG AAT GAG TA-3 0 . The experiment was repeated three times with similar results. The difference between the two groups was evaluated using a two-tailed, paired Student's ttest, with Po0.05 being considered as significant.
